Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial

Medicine and Dentistry

• Placebo 100%
• Patient 33%
• Acute Coronary Syndrome 33%
• Hazard Ratio 25%
• Combination Therapy 16%
• Randomized Clinical Trial 16%
• Inpatient 16%
• Serositis 8%
• Ischemia 8%
• Heart Muscle Revascularization 8%
• Group Therapy 8%
• Diarrhea 8%
• All Cause Mortality 8%
• Infarction 8%
• Apoplexy 8%
• Cardiovascular System 8%
• Odor 8%
• 1 Alkyl 2 Acetylglycerophosphocholine Esterase 8%
• ST Elevation 8%
• Amaurosis 8%
• Atherogenesis 8%

INIS

• coronaries 66%
• patients 50%
• hazards 25%
• solids 16%
• therapy 16%
• death 16%
• design 8%
• clinical trials 8%
• cardiovascular diseases 8%
• risks 8%
• mortality 8%
• inflammation 8%
• safety 8%
• inhibition 8%
• guidelines 8%
• ischemia 8%
• lipoproteins 8%
• odor 8%
• diarrhea 8%
• elevation 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Darapladib 75%
• Acute Coronary Syndrome 33%
• Death 16%
• Infarction 8%
• Ischemia 8%
• Diarrhea 8%
• All Cause Mortality 8%
• Atherogenesis 8%
• 1 Alkyl 2 Acetylglycerophosphocholine Esterase 8%
• Blindness 8%